Go to the list of all blogs
Allana's Avatar
published in Blogs
Aug 05, 2026
TickeronGET DAILY SIGNALS
Why Is Insulet Corporation (PODD) Stock Down -19.54% Today?

Why Is Insulet Corporation (PODD) Stock Down -19.54% Today?

Key Takeaways

  • Insulet Corporation shares plummeted approximately 19.5% on Wednesday, hitting a new 52-week low after the company reported second-quarter earnings.
  • The primary catalyst was a downward revision to full-year 2026 revenue growth guidance, driven by weaker U.S. Omnipod sales expectations and lower-than-expected Q3 revenue guidance.
  • Management disclosed retention and utilization challenges among type 2 diabetes patients, with CEO Ashley McEvoy acknowledging the company should have identified these issues sooner.
  • A securities-fraud class-action lawsuit alleging misrepresentations about Omnipod manufacturing controls and product-quality issues added further pressure to investor sentiment.
  • Several Wall Street analysts reduced price targets following the report, though some maintained outperform ratings, citing the stock's now-depressed valuation.
  • Traders are now watching for stabilization around technical support levels and any commentary on competitive dynamics in the insulin pump market.

Opening Summary

PODD, Insulet Corporation — the Acton, Massachusetts-based leader in tubeless insulin pump technology with its Omnipod brand — suffered one of its worst single-day selloffs in nearly two decades on Wednesday. Shares closed the prior session at $166.82 and cratered to approximately $134.23 in intraday trading, a decline of roughly 19.54%. The selloff was triggered by the company's second-quarter 2026 earnings release, which, despite beating both top- and bottom-line estimates, included a cut to full-year revenue growth guidance and a disappointing third-quarter outlook that spooked investors.

Q2 Earnings Beat Overshadowed by Guidance Cut

Insulet delivered what on paper looked like a strong quarter. Revenue rose 23.5% year-over-year to $801.7 million, exceeding the consensus estimate of approximately $787 million. Adjusted earnings per share came in at $1.66, comfortably above the $1.45 Wall Street had forecast. Total Omnipod revenue climbed 24.6% to $795.9 million, with international markets surging 35.5%.

However, investors fixated on the forward outlook. Management lowered its full-year 2026 total revenue growth guidance to 20%–22% in constant currency, down from the prior range of 21%–23%. More critically, the U.S. Omnipod growth forecast was cut to 17%–19% from 20%–22%. Third-quarter revenue guidance of $829.9 million to $844.0 million also landed below the roughly $846 million consensus. The implication — that the back half of 2026 will show a meaningful deceleration in the core U.S. business — proved to be the dominant narrative.

Type 2 Diabetes Retention Challenges Surface

Beneath the headline numbers, a more concerning story emerged. Insulet executives disclosed that retention and utilization trends among type 2 diabetes (T2) customers were running below prior expectations, particularly during the critical first 90 days of therapy. CEO Ashley McEvoy acknowledged on the earnings call that the company should have identified these emerging retention headwinds earlier. The disclosure raised questions about whether the rapid scaling into the T2 market — a key growth pillar for Insulet — is encountering structural friction that could weigh on long-term adoption curves.

Securities Fraud Class Action Adds Legal Overhang

Compounding the negative sentiment, a securities-fraud class-action lawsuit filed against Insulet and certain executives has drawn fresh attention. The complaint alleges that the company misrepresented Omnipod manufacturing controls, product safety, and the scope of device-quality issues. Multiple law firms have publicized the case, noting an August 31 lead-plaintiff deadline. While the allegations remain unproven, the legal overhang adds an additional layer of uncertainty at a time when investor confidence is already fragile.

Analyst Reactions: Price Targets Cut Across the Board

Several sell-side analysts moved quickly to adjust their models. Leerink Partners noted that the updated guidance implies second-half total sales roughly 2% below consensus, with U.S. Omnipod sales about 5% below Street expectations. Evercore ISI acknowledged the guidance cut would be "a source of much debate" and questioned whether a growth reacceleration in 2027 and beyond was credible as the base grows larger and competition enters the patch pump market. While some analysts maintained outperform ratings — citing the stock's now-depressed valuation — price targets were trimmed across the board.

Market Context and Trading Activity

The selloff in PODD was emphatic by any measure. Volume surged well above the stock's average daily turnover as institutional and retail participants rushed to reprice the shares. The stock sliced through its 50-day moving average and hit a new 52-week low, touching $131.40 at the session's nadir. The move also rippled through the broader medtech space, with medical products peer MDLN (Medline) falling in sympathy after cutting its own guidance. The S&P 500 traded higher on the day, underscoring that PODD's decline was a company-specific event rather than a macro-driven selloff.

What Comes Next for PODD

Insulet now faces a credibility challenge with the investment community. Management must demonstrate over the coming quarters that the U.S. growth slowdown is a temporary soft patch rather than the start of a structural deceleration. Key factors to watch include whether T2 retention metrics stabilize, whether international momentum — which remains robust at roughly 30% constant-currency growth — can offset domestic softness, and how the competitive landscape evolves as rivals target the patch pump and pharmacy channel. The raised adjusted EPS growth outlook (now above 30%) provides some counterbalance, but revenue trends will likely dominate the narrative. The company's next quarterly update will be pivotal in determining whether the stock can stage any meaningful recovery.

Trending AI Robots

For traders and investors seeking to navigate volatile market environments with data-driven strategies, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots. Tickeron provides hundreds of automated trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by trading strategy, timeframe, performance metrics, and the symbols they trade, allowing users to identify the approaches that are currently thriving. Explore the Trending AI Robots page to see which strategies are delivering results in today's market.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PODD

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


PODD sees MACD Histogram crosses below signal line

PODD saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 46 instances where the indicator turned negative. In 34 of the 46 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PODD moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 17 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.

The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PODD as a result. In 59 of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 66%.

PODD moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PODD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.

PODD broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 10-day moving average for PODD crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 50%.

Following a +7.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where PODD advanced for three days, in 208 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 66%.

The Aroon Indicator entered an Uptrend today. In 91 of 174 cases where PODD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 52%.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. PODD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.145) is normal, around the industry mean (4.142). P/E Ratio (27.334) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.047) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (3.294) is also within normal values, averaging (40.124).

The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PODD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -11%. For the same Industry, the average monthly price growth was -15%, and the average quarterly price growth was -18%. MXCT experienced the highest price growth at 15%, while CODX experienced the biggest fall at -50%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -35%. For the same stocks of the Industry, the average monthly volume growth was -2% and the average quarterly volume growth was -21%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 64
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 16 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of insulin infusion systems

Industry MedicalNursingServices

Industry
Medical Specialties
Address
100 Nagog Park
Phone
+1 978 600-7000
Employees
5400
Web
https://www.insulet.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.